MOAI
LIVE

Serial Number

79379585

Owner

Anima Biotech Inc.

Attorney

Jonathan D. Reichman, Esq.

Filing Date

Jul 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MOAI Trademark

Serial Number: 79379585 • Registration: 7602277

MOAI is a trademark filed by Anima Biotech Inc. on July 3, 2023. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Anima Biotech Inc. (5 trademarks)

75 Claremont Rd, Ste 102

Entity Type: 03

Trademark Details

Filing Date

July 3, 2023

Registration Date

December 17, 2024

Published for Opposition

October 29, 2024

Goods & Services

Downloadable Computer software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; downloadable computer software for use in the research and development of pharmaceutical preparations; downloadable computer software for use in the pharmaceutical drug development and discovery; downloadable computer software for the analysis of biological or chemical activity; downloadable computer software for the analysis of pharmaceutical properties of molecules; downloadable computer software for the identification and analysis of biological targets, networks and pathways; downloadable data processing software; downloadable computer software for creating searchable databases of information and data; downloadable computer software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; downloadable computer software for compiling and analyzing scientific, pharmaceutical and medical data; downloadable computer software for use in accessing and importing data and information; downloadable interactive databases in the fields of science, medicine and pharmaceuticals; downloadable computer software for big data analytics

Pharmaceutical, and scientific research and development; medical research and development in the field of disease mechanisms, therapeutics and pharmaceuticals; scientific research and technological research services in the field of pharmaceuticals and molecular biology; research and development of pharmaceutical preparations and medicines; pharmaceutical drug development and discovery services; providing online non-downloadable software data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; providing online non-downloadable software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; providing online non-downloadable software for the analysis of pharmaceutical properties of molecules; providing online non-downloadable software for the identification and analysis of biological targets, networks and pathways; providing online non-downloadable data processing software; providing online non-downloadable software for creating searchable databases of information and data; platform as a service (PAAS) featuring computer software platforms for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; software as a service (SAAS) services featuring software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; data mining; providing online non-downloadable software for use in accessing, importing, compiling and analyzing scientific, pharmaceutical and medical data and information; providing online non-downloadable software for big data analytics; research and development of new products; cloud computing featuring software for data compiling, accessing, importing, searching, tracking, exploration, processing, integration, and analysis in the fields of science, medicine and pharmaceuticals; providing medical and scientific research information, advisory and consultancy services in the field of pharmaceuticals and molecular biology; providing information, advisory and consultancy services regarding research and development of pharmaceutical preparations and medicines

Filing History

CORRECTION UNDER SECTION 7 - PROCESSED
Jun 24, 2025 COC.
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 21, 2025 FINO
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 17, 2025 APRE
FINAL DISPOSITION NOTICE SENT TO IB
May 28, 2025 FICS
FINAL DISPOSITION PROCESSED
May 28, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 17, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 14, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 27, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 27, 2025 OPNR
TEAS SECTION 7 REQUEST RECEIVED
Jan 24, 2025 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
POST PUBLICATION AMENDMENT – NOT ENTERED
Dec 12, 2024 CHPN
ASSIGNED TO PETITION STAFF
Dec 5, 2024 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Nov 6, 2024 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 29, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 29, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 9, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 19, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 19, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 13, 2024 TROA
REFUSAL PROCESSED BY IB
May 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 12, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 12, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 25, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 15, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 3, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 28, 2023 REPR